I-Mab Stock Price, News & Analysis

Genexine, a clinical-stage biopharmaceutical company, announces the appointment of Neil Warma as President and CEO. With over 25 years of leadership in healthcare, Warma aims to enhance global drug development and commercialization. The company focuses on expanding its pipeline, particularly in immunotherapeutics and long-acting biologics, and plans to file several important BLAs in the next 1-3 years. Genexine is currently conducting over 20 clinical trials, including Phase 3 studies, with initial data expected soon, which could drive shareholder value.

I-Mab (Nasdaq: IMAB) will hold a conference call on May 27 at 8 a.m. EST to present preliminary data from its ongoing phase 2 clinical trial of uliledlimab (TJD5), a differentiated CD73 antibody. This compound aims to enhance anti-tumor immune responses in combination with established checkpoint therapies. The call will also outline the global clinical development plan for uliledlimab, which is positioned to potentially offer significant clinical benefits in immuno-oncology.

I-Mab (Nasdaq: IMAB) provided updates regarding its status under the Holding Foreign Companies Accountable Act (HFCAA) following the SEC's provisional identification of the company as a "Commission-Identified Issuer." This identification occurred after I-Mab filed its annual report on Form 20-F for FY 2021, which included an audit report the PCAOB could not fully inspect. While this does not lead to immediate delisting, continued identification for three years may result in prohibited trading in the U.S. I-Mab is engaging an independent auditor to comply with HFCAA requirements, aiming for completion in H2 2022.

I-Mab (Nasdaq: IMAB) announces key appointments to enhance its leadership team. Richard Yeh has been appointed as Chief Operating Officer, with over 25 years of experience in the biopharmaceutical industry, particularly in investor relations and strategic operations. Dr. John Hayslip joins as Chief Medical Officer, bringing nearly two decades of oncology expertise to accelerate clinical development. This strategic move aims to support I-Mab's ambition of becoming a leading global biopharmaceutical company, focusing on innovative therapies for immuno-oncology diseases.

I-Mab (Nasdaq: IMAB) announced a 180-day voluntary lock-up of shares by key shareholders including CBC Group and Hony Capital, effective March 31, 2022. This decision reflects the shareholders' confidence in I-Mab's transformation into a fully integrated biopharma company. The lock-up involves 51,226,814 ordinary shares, representing 26.8% of total outstanding shares. Concurrently, I-Mab will register approximately 37.7 million ordinary shares to satisfy contractual registration rights, while the shareholders express no intention to sell during the lock-up period.

I-Mab (Nasdaq: IMAB) reported strong financial results for 2021, achieving numerous clinical milestones, including key data readouts for lemzoparlimab, uliledlimab, and felzartamab. The company established a $315M strategic partnership with Jumpcan for eftansomatropin alfa, advancing its pipeline with 10 clinical-stage assets, primarily in Phases 2 and 3. I-Mab expects 3-4 BLA filings between 2023-2025, supported by a robust cash position of $671M. With ongoing global expansions, the company is positioned for significant growth in the biopharmaceutical sector.

I-Mab, a clinical-stage biopharmaceutical company (Nasdaq: IMAB), will announce its full-year 2021 financial results on March 29, 2022, before the market opens. A conference call will follow at 8:00 a.m. EST to discuss the results and provide corporate updates. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, with over 20 clinical and preclinical drug candidates. The company aims to transition into a fully integrated global biopharmaceutical entity, enhancing its R&D and manufacturing capabilities.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has provided updates regarding the Holding Foreign Companies Accountable Act (HFCAA). As of March 8, 2022, I-Mab is not listed as a 'Commission-Identified Issuer' by the SEC. To ensure compliance, the company plans to engage an accounting firm subject to PCAOB inspection for its fiscal year 2022 audit. I-Mab is also pursuing a dual listing on the Hong Kong Stock Exchange to enhance trading flexibility for shareholders, pending market conditions and regulatory approvals.

I-Mab (Nasdaq: IMAB) announced multiple poster presentations at the AACR 2022 Annual Meeting, showcasing findings on enoblituzumab and TJ-C64B. Enoblituzumab, a monoclonal antibody targeting B7-H3, is under Phase 2 trials in China for solid tumors, and data highlights its anti-tumor activity and potential for combination therapies. TJ-C64B, a bispecific antibody, shows promise for treating CLDN6-positive tumors while minimizing liver toxicity. These presentations reflect I-Mab's commitment to advancing its innovative pipeline in cancer therapeutics.